BRYOSTATIN 1 THERAPY OF METASTATIC MELANOMA
BRYOSTATIN 1 THERAPY OF METASTATIC MELANOMA
批准号:
2112199
负责人:
Andrew S Kraft
金额:
$12.98万
依托单位国家:
美国
项目类别:
财政年份:
1995
资助国家:
美国
项目状态:
已结题
起止时间:
1995-09-15 至 1996-07-31
关键词:
antineoplastics apoptosis bioassay biopsy clinical trials drug administration rate /duration drug screening /evaluation enzyme activity gene expression hematopoietic stem cells human subject human therapy evaluation interleukin 6 melanoma metastasis monoclonal antibody neoplasm /cancer chemotherapy neoplasm /cancer immunology neoplasm /cancer pharmacology neoplastic cell pharmacokinetics protein kinase C tumor necrosis factor alpha
中文摘要
描述:(申请者摘要)申请者建议完成
新型抗癌药物Bryostatin-1治疗转移的II期研究
黑色素瘤,并使用实验室研究来评估生物化学,
该药剂的作用机理和药理作用。Bryostatin I是一种
从海洋苔藓虫中分离出的大环内酯,其功能通过
激活蛋白激酶C。他和其他人已经证明
抑制动物黑色素瘤的生长。这些结果导致了阶段
I在人体内测试Bryostatin 1,确定了剂量和时间表
用于给药Bryostatin 1,并证明Bryostatin
1有一组有限的副作用。在I期测试中,两名患者
转移性黑色素瘤对这种药物有部分反应。目标
这项第二阶段试验的内容是:(1)进行第二阶段研究
Bryostatin-1,并评估转移患者的百分比
黑色素瘤对该制剂的反应;(2)确定Bryostatin是否
1诱导肿瘤标本细胞凋亡:(3)检测肿瘤是否
反应与蛋白激酶C或基因的调节有关
诱导;(4)确定Bryostatin 1是否激活淋巴细胞
杀灭肿瘤组织;(5)完成Bryostatin 1药理
使用一种新的化验方法。在这项初步研究中,申请人提议
使用既定的I期方案治疗14名患者,每周一次
每4周中有3周以25ug/m2的剂量输注超过1小时。如果
在第一批14名患者中看到了反应,总共有25名患者将
接受治疗。未接受任何化疗或免疫治疗的患者
并有容易活检的病变将符合条件。黑色素瘤的活检
治疗前后将进行损伤检查,以评估生物标志物和
中间端点。在采血前、采血期间和采后采血
输液和检查血小板和中性粒细胞活化,蛋白质
蛋白激酶水平和基因转录的变化。只要是部分的
或完全缓解,将继续治疗。
英文摘要
DESCRIPTION: (Applicant's Abstract) The applicant proposes to accomplish
a phase II study of the novel anticancer agent Bryostatin 1 in metastatic
melanoma and use laboratory investigations to evaluate the biochemistry,
mechanism of action and pharmacology of this agent. Bryostatin I is a
macrocyclic lactone isolated from a marine Bryozoan which functions by
activating protein kinase C. He and others have demonstrated that it
inhibits the growth of melanoma in animals. These results led to phase
I testing of Bryostatin 1 in humans which defined a dose and schedule
for the administration of Bryostatin 1 and demonstrated that Bryostatin
1 had a limited set of side effects. In phase I testing two patients
with metastatic melanoma had a partial response to this agent. The aims
of this phase II trial are: (1) to carry out a phase II study of
bryostatin 1 and evaluate the percentage of patients with metastatic
melanoma responding to this agent; (2) to determine whether bryostatin
1 induces apoptosis in tumor samples: (3) to examine whether tumor
responses correlate with the regulation of protein kinase C or gene
induction; (4) to determine whether bryostatin 1 activates lymphocytes
to kill tumor tissues; and (5) to accomplish Bryostatin 1 pharmacology
using a novel assay. For this pilot study the applicant proposes to
treat 14 patients using an established phase I regimen once a week every
three out of four weeks at a dose of 25 ug/m2 infused over one hour. If
a response is seen in the first 14 patients, a total of 25 patients will
be treated. Patients who have not received any chemo- or immunotherapy
and have easily biopsied lesions will be eligible. Biopsies of melanoma
lesions will be done before and after therapy to assess biomarkers and
intermediate end points. Blood will be drawn before, during and after
infusion and examined for platelet and neutrophil activation, protein
kinase levels and changes in gene transcription. As long as a partial
or complete response is evident, treatment will be continued.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Regulation of RNA Decapping and Degradation: A novel approach to prostate cancer therapy
-
批准号:10758110
-
项目类别:
-
资助金额:$39.72万
-
财政年份:2023
-
负责人:Andrew S Kraft
-
依托单位:
Pim 1 Protein Kinase in Regulating Stromal Cell Biology in Prostate Cancer
-
批准号:8855025
-
项目类别:
-
资助金额:$19.96万
-
财政年份:2015
-
负责人:Andrew S Kraft
-
依托单位:
MUSC/HCC Paul Calabresi Clinical Oncology Training Program Plan
-
批准号:8486908
-
项目类别:
-
资助金额:$16.38万
-
财政年份:2013
-
负责人:Andrew S Kraft
-
依托单位:
Targeting the Pim 1 Protein Kinase to Overcome Resistance to AKT Inhibitors
-
批准号:8577635
-
项目类别:
-
资助金额:$31.02万
-
财政年份:2013
-
负责人:Andrew S Kraft
-
依托单位:
Targeting the Pim 1 Protein Kinase to Overcome Resistance to AKT Inhibitors
-
批准号:9039263
-
项目类别:
-
资助金额:$22.86万
-
财政年份:2013
-
负责人:Andrew S Kraft
-
依托单位:
Targeting the Pim 1 Protein Kinase to Overcome Resistance to AKT Inhibitors
-
批准号:8735893
-
项目类别:
-
资助金额:$7.23万
-
财政年份:2013
-
负责人:Andrew S Kraft
-
依托单位:
Targeting the Pim 1 Protein Kinase to Overcome Resistance to AKT Inhibitors
-
批准号:9320825
-
项目类别:
-
资助金额:$31.85万
-
财政年份:2013
-
负责人:Andrew S Kraft
-
依托单位:
Targeting the Pim 1 Protein Kinase to Overcome Resistance to AKT Inhibitors
-
批准号:8891388
-
项目类别:
-
资助金额:$31.11万
-
财政年份:2013
-
负责人:Andrew S Kraft
-
依托单位:
Senior Leadership
-
批准号:8533978
-
项目类别:
-
资助金额:$6.58万
-
财政年份:2012
-
负责人:Andrew S Kraft
-
依托单位:
LIPIDOMICS SHARED RESOURCE GROUP
-
批准号:8695810
-
项目类别:
-
资助金额:$8.14万
-
财政年份:2009
-
负责人:Andrew S Kraft
-
依托单位:
BIOSTATISTICS SHARED RESOURCE GROUP
-
批准号:8695824
-
项目类别:
-
资助金额:$12.18万
-
财政年份:2009
-
负责人:Andrew S Kraft
-
依托单位:
CELL AND MOLECULAR IMAGING
-
批准号:8695817
-
项目类别:
-
资助金额:$7.26万
-
财政年份:2009
-
负责人:Andrew S Kraft
-
依托单位:
Medical University of South Carolina - Cancer Center Support Grant
-
批准号:8923675
-
项目类别:
-
资助金额:$14.74万
-
财政年份:2009
-
负责人:Andrew S Kraft
-
依托单位:
Medical University of South Carolina - Cancer Center Support Grant
-
批准号:8322869
-
项目类别:
-
资助金额:$5.76万
-
财政年份:2009
-
负责人:Andrew S Kraft
-
依托单位:
Novel Inhibitors of Pim Protein Kinases
-
批准号:7743696
-
项目类别:
-
资助金额:$25.79万
-
财政年份:2009
-
负责人:Andrew S Kraft
-
依托单位:
Medical University of South Carolina - Cancer Center Support Grant
-
批准号:7795202
-
项目类别:
-
资助金额:$155.75万
-
财政年份:2009
-
负责人:Andrew S Kraft
-
依托单位:
BIOREPOSITORY & TISSUE ANALYSIS
-
批准号:8695842
-
项目类别:
-
资助金额:$6.65万
-
财政年份:2009
-
负责人:Andrew S Kraft
-
依托单位:
Medical University of South Carolina - Cancer Center Support Grant
-
批准号:7931536
-
项目类别:
-
资助金额:$254.87万
-
财政年份:2009
-
负责人:Andrew S Kraft
-
依托单位:
CANCER CONTROL
-
批准号:8695807
-
项目类别:
-
资助金额:$3.08万
-
财政年份:2009
-
负责人:Andrew S Kraft
-
依托单位:
Medical University of South Carolina - Cancer Center Support Grant
-
批准号:8072105
-
项目类别:
-
资助金额:$140.13万
-
财政年份:2009
-
负责人:Andrew S Kraft
-
依托单位:
国内基金
海外基金
登录
查看更多内容
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
-
批准号:LBY21H010001
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2020
-
负责人:郑绪阳
-
依托单位:
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
-
批准号:81703335
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2017
-
负责人:卫高菲
-
依托单位:
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
-
批准号:81670594
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2016
-
负责人:陈昊
-
依托单位:
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
-
批准号:81470791
-
项目类别:面上项目
-
资助金额:73.0万元
-
批准年份:2014
-
负责人:董家鸿
-
依托单位:
Apoptosis signal-regulating kinase 1是七氟烷抑制小胶质细胞活化的关键分子靶点?
-
批准号:81301123
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2013
-
负责人:王海莲
-
依托单位:
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
-
批准号:81101529
-
项目类别:青年科学基金项目
-
资助金额:22.0万元
-
批准年份:2011
-
负责人:陈雪芹
-
依托单位:
放疗与细胞程序性死亡(APOPTOSIS)相关性及其应用研究
-
批准号:39500043
-
项目类别:青年科学基金项目
-
资助金额:9.0万元
-
批准年份:1995
-
负责人:梁克
-
依托单位: